Pembrolizumab + Lenvatinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroendocrine Tumors
Conditions
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
Trial Timeline
Dec 15, 2017 → May 13, 2024
NCT ID
NCT03290079About Pembrolizumab + Lenvatinib
Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03290079. Target conditions include Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07011849 | Phase 2 | Withdrawn |
| NCT06266338 | Phase 2 | Recruiting |
| NCT05545969 | Phase 2 | Withdrawn |
| NCT04865887 | Phase 2 | Recruiting |
| NCT05273554 | Phase 1 | Active |
| NCT04955743 | Phase 2 | Terminated |
| NCT05147558 | Phase 2 | Active |
| NCT05078931 | Phase 2 | Active |
| NCT04848337 | Phase 2 | Active |
| NCT04729348 | Phase 2 | Terminated |
| NCT04287829 | Phase 2 | Active |
| NCT04207086 | Phase 2 | Active |
| NCT03290079 | Phase 2 | Completed |
Competing Products
20 competing products in Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| [212Pb] VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 2 | 52 |
| Avelumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab Injection | Merck | Phase 2 | 52 |
| Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab | Merck | Phase 1 | 33 |
| Avelumab | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 52 |
| MK-0646 | Merck | Phase 2 | 52 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |